Unfortunately, MVP is a one trick pony. The respiratory products do not produce enough revenue and are unlikely to grow significantly. Lot's of growth to come from Penthrox but that leaves MVP open to risk from competitors.
- Forums
- ASX - By Stock
- Movement
Unfortunately, MVP is a one trick pony. The respiratory products...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MVP (ASX) to my watchlist
|
|||||
Last
48.0¢ |
Change
-0.005(1.03%) |
Mkt cap ! $41.85M |
Open | High | Low | Value | Volume |
48.0¢ | 48.5¢ | 47.5¢ | $2.51K | 5.268K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 82 | 48.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.5¢ | 2478 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4743 | 0.475 |
1 | 28211 | 0.470 |
1 | 2323 | 0.465 |
1 | 2200 | 0.450 |
1 | 1200 | 0.440 |
Price($) | Vol. | No. |
---|---|---|
0.485 | 403 | 2 |
0.495 | 2021 | 1 |
0.510 | 8535 | 2 |
0.515 | 4000 | 1 |
0.520 | 1150 | 1 |
Last trade - 12.27pm 25/07/2024 (20 minute delay) ? |
Featured News
MVP (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online